Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Johnson & Johnson’s Janssen Pharmaceuticals unit has agreed to license hepatitis C drug assets from Achillion Pharmaceuticals, a developer of small-molecule drugs for infectious diseases. Janssen will invest $225 million in Achillion stock plus up to $1.1 billion in potential development, regulatory, and sales milestone payments. Achillion’s lead compound, ACH-3102, is a second-generation NS5A inhibitor now in Phase II clinical trials. J&J already markets the older treatment Olysio, but the firm isn’t a player in the newer all-oral market.
This article has been sent to the following recipient: